Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.
about
Exploiting the critical perioperative period to improve long-term cancer outcomesSipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.Proposed mechanisms of action for prostate cancer vaccines.A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancerPSA regulates androgen receptor expression in prostate cancer cells.Update on prostate cancer vaccinesAntigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinationsChitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines.Modification of Antigen Impacts on Memory Quality after Adenovirus Vaccination.Sipuleucel-T: immunotherapy for advanced prostate cancer.DNA vaccines for the treatment of prostate cancer.Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors.CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.Cancer immunotherapy: a paradigm shift for prostate cancer treatment.Prostate cancer vaccines in clinical trials.Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen?Applying biodegradable particles to enhance cancer vaccine efficacy.Prostate cancer vaccines in combination with additional treatment modalities.Immunotherapy in prostate cancer: review of the current evidence.DNA vaccination for prostate cancer: key concepts and considerations.Adenovirus-vectored Ebola vaccines.Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.Immunotherapy for prostate cancer: False promises or true hope?Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.Vaccine Design: Replication-Defective Adenovirus Vectors.Prostate cancer vaccines: Update on clinical development.Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.Vaccine immunotherapy for prostate cancer: from mice to men.Prostate cancer vaccines: an old yet novel target, the androgen receptor.Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).Long-term toxicity, pharmacokinetics and immune effects of a recombinant adenovirus vaccine expressing human papillomavirus 16 E6 and E7 proteins (HPV16 E6E7-Ad5 Vac) in primates.The Journey of Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy RoadImproving adenoviral vectors and strategies for prostate cancer gene therapy
P2860
Q33871661-166F49B4-EE49-456A-A660-C164FE785B11Q35128716-1944553C-D4F7-47CB-9152-ADCD3006A1EEQ35174754-5CB93E01-F0D4-4741-BEFC-E917E8433996Q36005476-49AAE765-D841-460A-AED9-B36CE8D4DEADQ36114365-2031079B-B57A-4374-A23E-F8B174030535Q36169608-9BF824EC-6402-437F-804C-3F56F9149555Q36569221-972C0567-4280-460B-A168-73D7724CD87BQ36582241-DDFA94D7-7947-4601-B346-E254921E7609Q36770950-10BEB34F-A502-4223-9D2B-C8963B6657BCQ37283724-61659DD3-7C63-4F1B-B544-75321ED2A83DQ37771942-E890A3B1-A30C-476C-BD71-F7C285265FFFQ37932525-B1808FD9-DB87-4E1E-A2B9-41D24BB6ABEAQ37974160-6544157C-1829-493A-A8AC-E8B15AB62BDFQ37989571-F45E8077-23FC-436F-A6E4-E765EBA90B4EQ38013964-2D2B59E9-E44C-442B-825F-E9E9165B4D81Q38036690-5E21BC2A-DF11-49F9-9450-0A8F9F6C19B6Q38133654-6A268B35-C9CE-419D-BEE9-A6A5A7CB86BDQ38212549-D331A751-173A-4398-9EAE-F339C3938DBAQ38212571-8085F9AD-78C1-470B-8E99-E516503DF601Q38283918-95803CD5-922A-4FE8-AEF0-97BE97BFE84CQ38544772-6CE8CC8B-BDFE-4E0B-B1DF-AFC119B924C3Q38569831-116F7A6F-7AAC-4BB2-B35E-997FA8215372Q38760061-33692B47-9AD5-46EE-8B68-E7C92812A7D5Q38959645-021B7F10-9FAD-4AFD-A8FE-C0680439E8B7Q39525614-1D61A3C4-2A25-4B17-BFAF-DE755B0A7FB0Q39538214-898FD879-4B21-4029-81D7-3FE7A689F0EEQ40087457-71C5F6BD-AAE7-426B-9C54-8EC778D4EF8FQ40801619-8A6C9C24-1C84-44C5-A0A2-253D35E73505Q41220895-622EE87F-17B3-4AFE-B22F-47F19B64BEEEQ41992352-F2B8B417-FAB8-4A1B-B83D-3AA10868BCB6Q42217435-2613A662-465C-4417-89DB-6CE5E5820F1BQ45726626-D0F162A7-C626-4B3B-B8DB-E95B15888F14Q47759603-37FC0BAC-E3C1-4AF1-912D-9A7A7C1BA19BQ48316638-35C99E63-F1A1-4037-B0D7-9E92A14FB5C3Q54968953-BC953B6D-8C08-4C98-B7D8-63CA810C0510Q58750585-21AB3E2E-4FD5-4DA3-B9B4-58814DC1F43DQ58801177-AA151AC2-910C-47CD-8C57-41DF8478C508
P2860
Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Phase I clinical trial of an a ...... afety and immunologic results.
@en
Phase I clinical trial of an a ...... afety and immunologic results.
@nl
type
label
Phase I clinical trial of an a ...... afety and immunologic results.
@en
Phase I clinical trial of an a ...... afety and immunologic results.
@nl
prefLabel
Phase I clinical trial of an a ...... afety and immunologic results.
@en
Phase I clinical trial of an a ...... afety and immunologic results.
@nl
P2093
P2860
P1476
Phase I clinical trial of an a ...... safety and immunologic results
@en
P2093
Badrinath R Konety
David M Lubaroff
Diana Boeglin
Jack Gerstbrein
Jeanne Howard
Jennifer Paisley
Mary Shannon
Richard D Williams
Tammy Madsen
Timothy L Ratliff
P2860
P304
P356
10.1158/1078-0432.CCR-09-1910
P407
P50
P577
2009-11-17T00:00:00Z